Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes

Fig. 2

Probability of events of mortality and CV outcomes with incretin-based agents versus placebo. Effect of incretin-based agents on all-cause mortality (a), CV mortality (b), MACE (c), nonfatal MI (d), nonfatal stroke (e) and heart failure hospitalization (f) was analyzed individually. CI confidence interval, DPP-4I dipeptidyl peptidase-4 inhibitor, GLP-1A glucagon-like peptide-1 agonist, CV cardiovascular, MACE major cardiovascular events, MI myocardial infarction

Back to article page